. Author manuscript; available in PMC: 2019 Aug 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2018 Apr 12;24(8):1759–1765. doi: 10.1016/j.bbmt.2018.03.031

Table 1A.

Characteristics and outcomes of 2 patients with sickle cell disease that underwent HSCT from a haploidentical, related donor with the alemtuzumab, TBI, and PTCy.

	Transplantation Characteristics							Transplantation Outcomes			Transplant-Related Toxicity
No.	Age at HSCT (years)	Sex	Hemoglobin Genotype	Indications*	Prior Therapy	Donor	CD34⁺ Dose (×10⁶/kg)	Duration Follow-up (months)	Living Status	Neutrophil Engraftment	Infectious Complications	CMV Reactivation	aGVHD	cGVHD
A	24	F	SS	20 VOC/year 3 ACS/lifetime	Hydroxyurea	Mother (Hb AS)	5.9	37	Alive	Autologous, Day +39	None	None	None	None
B	52	M	SC	10 VOC/year	Hydroxyurea	Sister (Hb AA)	5.4	36	Alive	Autologous, Day +34	None	Day +11	None	None